Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Prospective Study of Acalabrutinib in Chronic Lymphocytic Leukemia Therapy in Real Clinical Practice in Belarus.

NCT07288515 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07288515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07288515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Prospective Study of Acalabrutinib in Chronic Lymphocytic Leukemia Therapy in Real Clinical Practice in Belarus.
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
December 31, 2025
Completion date
December 31, 2029
Enrollment
50 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia